EXIS™ Platform: Pioneering Precision in Antibody Discovery

Name: EXIS™ Platform
Brand: Prellis Biologics
Availability: InStock

EXIS™ unlocks the human immune system for true human antibody discovery and exploits the large genetic diversity from multiple donors while breaking tolerance to human antigens. In addition, our AI/ML platform triages the depth and diversity of the antibody responses to deliver broad epitope coverage and fully human antibodies with an intrinsically low immunogenic risk profile – harnessing the benefits of in vivo antibody generation while delivering the flexibility of an in vitro antibody platform.

EXIS™ taps into diverse genetics for antibody discovery, breaking tolerance to human antigens. Its AI/ML platform provides broad epitope coverage, low immunogenic risk, and flexibility, combining in vivo and in vitro approaches.

Our Technology

Prellis’ EXIS™ platform recaptures human immune biology in 3D-printed organoids for the rapid discovery of diverse antibodies for the next generation of therapeutics.

Human Immune Cell Diversity

3D Bioprinted LNO™ Construction

B-cell Activation and Library Creation

Antibody Screening Selection

AI-Guided Screening

AI Optimisation

Our Technology

Prellis’ EXIS™ platform recaptures human immune biology in 3D-printed organoids for the rapid discovery of diverse antibodies for the next generation of therapeutics.

Human Immune Cell Diversity

3D Bioprinted LNO™ Construction

B-cell Activation and Library Creation

Antibody Screening Selection

AI-Guided Screening

AI Optimisation

Human Immune Cell Diversity

Our journey towards groundbreaking therapies begins with harnessing the vast diversity of human immune cells from multiple donors, which forms the robust foundation of the EXIS™ platform. By tapping into the unique immune repertoires of different individuals, we unlock a wealth of antibody possibilities and increase the likelihood of discovering highly effective therapeutic candidates with an intrinsically low immunogenic risk profile.

3D Bioprinted LNO™ Construction

Immune cells are incorporated into 3D scaffolds from our two-photon holography bioprinters to generate Lymph Node Organoids (LNO™). This enables our platform to mimic natural antibody production in vitro, while accessing the full diversity of the immune repertoire.

B-cell Activation and Library Creation

The lymph node organoids are exposed to the target antigen, triggering B-cells to undergo somatic hypermutation, maturation, and differentiation to produce a wide array of antibodies specific to the antigen. This process generates a diverse library of potential therapeutic candidates, directly stemming from the human immune repertoire.

Antibody SequencingAntibody Selection and Screening

A pool of antigen-specific B-cells in the lymph node organoids is collected and sequenced to obtain antibody gene sequences. This yields a vast library of antibody sequences, each representing a potential therapeutic candidate.A subset of the large library of antibody sequences is selected and screened against the antigen. This allows us to obtain relevant data on which antibody sequences have desirable binding and functional attributes.

AI-model training and predictionAI-Guided Screening

The characterization data set obtained from the initial screening efforts is used to train an AI model that learns and ultimately predicts and guides further screening of the remaining B-cell library. The AI model selects additional sequences to screen, which are predicted to have desirable antibody attributes.Selected sequences are once again screened in the lab against the antigen. The resulting data can then be used to refine the AI model, creating a virtuous lab-loop that greatly increases hit rates and screening efficiency. Additionally, our AI models can guide screening efforts to scout for maximum diversity or alternatively hone in on specific antibody attributes.

AI Optimization

The totality of screening data is used to train generative AI models that can further refine antibody attributes for the desired function. Through iterative cycles of AI predictions and experimental validation, the antibody pool is efficiently optimized. The culmination of our efforts: highly specific, optimized antibodies, with low immunogenicity risk, poised to transform therapeutic development.

Key Features

Human Immune Diversity

Exploits the full genetic diversity from multiple blood donors to access a vast immune repertoire for fully human antibody discovery with low immunogenicity risk.